US-Indonesia Trade Deal Raises Concerns Over Reciprocity and Sovereignty

In February 2026, the United States and Indonesia signed a bilateral trade agreement intended to foster economic cooperation. However, a detailed examination of the Agreement Between the United States of America and the Republic of Indonesia on Reciprocal Trade reveals a significant imbalance in obligations, raising concerns about Indonesia’s regulatory sovereignty and the true nature of the “reciprocity” promised in the agreement’s title.

Asymmetrical Obligations: A One-Sided Agreement?

The agreement’s structure is characterized by a stark disparity in the obligations placed upon each nation. While the agreement’s title suggests mutual benefit, the text overwhelmingly details requirements imposed on Indonesia, framed using strong, mandatory language like “Indonesia shall.” Conversely, US commitments are often expressed with weaker phrasing such as “the United States shall function with,” “the United States may,” or “the United States commits to establishing a mechanism.”

This distinction in language is critical in international treaty law. “Shall” denotes a legally binding obligation, while “may” indicates discretionary action. The agreement requires Indonesia to undertake a comprehensive list of actions in exchange for reduced US tariffs, which fall from a maximum of 32 percent to 19 percent. These include:

• Opening markets to US agricultural products.
• Removing local content requirements for goods.
• Accepting US Food and Drug Administration (FDA) standards in place of Indonesian oversight by the National Agency of Drug and Food Control (BPOM).
• Exempting US products from Indonesian halal certification requirements.
• Aligning sanctions and export control policies with the United States.
• Purchasing $33 billion worth of US products.
• Prohibiting new trade agreements with countries deemed to “threaten essential US interests.”

In contrast, concrete US commitments are limited to reciprocal tariff reductions and a non-binding promise to “consider” financing support through the US Export-Import Bank (EXIM) and the US International Development Finance Corporation (DFC). The agreement lacks specific numerical targets, deadlines, or enforceable mechanisms for US compliance.

Erosion of Regulatory Sovereignty

A central concern is the potential erosion of Indonesia’s regulatory sovereignty across multiple sectors. The agreement’s provisions regarding product standards and certification processes are particularly problematic.

Pharmaceuticals and Food Safety

In the pharmaceutical and medical device sectors, Indonesia is obligated to accept FDA approval as sufficient evidence of product safety and efficacy, effectively ceding some oversight authority to a foreign agency. BPOM, Indonesia’s regulatory body, would be limited in its ability to independently assess the safety and quality of US-manufactured products. Similarly, the agreement requires Indonesia to recognize the US food safety system as meeting Indonesian standards without independent verification.

Halal Certification

Perhaps the most sensitive aspect of the agreement concerns halal certification. Indonesia, a country with a large Muslim population, requires many products, including cosmetics and medical devices, to be certified halal to ensure they comply with Islamic dietary laws. The agreement mandates that Indonesia exempt US-manufactured products from these requirements, potentially impacting consumer confidence and religious practices. Reuters reported on the controversy surrounding this provision, highlighting concerns from Indonesian Islamic organizations.

Implications and Future Outlook

The US-Indonesia trade agreement, while presented as a step towards strengthened economic ties, raises significant questions about fairness and national sovereignty. The asymmetrical obligations and the potential for diminished regulatory control warrant further public scrutiny and debate. Indonesia’s government faces the challenge of balancing the potential economic benefits of the agreement with the need to protect its national interests and regulatory autonomy. The long-term implications of this agreement will depend on how effectively Indonesia can navigate these competing priorities and ensure that the promised “reciprocity” translates into genuine mutual benefit.

Key Takeaways

• The US-Indonesia trade agreement exhibits a significant imbalance in obligations, with Indonesia bearing the brunt of the requirements.
• The agreement’s language, using “shall” for Indonesian obligations and “may” for US commitments, highlights the lack of binding commitments from the United States.
• Indonesia’s regulatory sovereignty is potentially compromised in key sectors like pharmaceuticals, food safety, and halal certification.
• The agreement raises concerns about the true meaning of “reciprocity” and the potential for exploitation of Indonesia’s economic interests.